Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Multicentre EECP CHF (congestive heart failure) trial gains FDA go-ahead:

This article was originally published in Clinica

Executive Summary

Vasomedical has received US FDA approval, with conditions, to perform a multicentre, controlled study of its enhanced external counterpulsation (EECP) therapy in congestive heart failure patients. The 18-centre study will assess EECP therapy, which involves wrapping pressurised cuffs around a patient's legs, in 180 subjects. The Westbury, New York company also said that the FDA has classified the EECP system as a Class III PMA device when used in the treatment of CHF.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT076984

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel